BMF-650 Phase 1 Clinical Trial Results: Critical Early Data
BMF-650 Phase 1 clinical trial results: 1.5% to 3.2% weight loss in outpatient cohorts; a 6.1% cohort had similar placebo loss. Early, unapproved.
Zealand Pharma Generate Biomedicines Deal: Powerful AI Pact
Zealand Pharma Generate Biomedicines deal: $30M upfront and up to nearly $1.2B in potential milestones for AI-designed obesity drugs. Nothing is guaranteed.